Effectiveness of sequential v. Standard triple therapy for treatment of Helicobacter pylori infection in children in Nairobi, Kenya

South African Medical Journal

Volumn 103, Issue 12, 2013, Pages 921-924

  Laving, A ^a,b   Kamenwa, R ^b   Sayed, S ^b   Kimang'a, A N ^c   Revathi, G ^b  

^a UNIVERSITY OF NAIROBI   (Kenya)

^b AGA KHAN UNIVERSITY   (Kenya)

^c JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Kenya)

Author keywords

Helicobacter pylori; Paediatrics; Sequential therapy; Triple therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE; TINIDAZOLE;

ABDOMINAL PAIN; ADOLESCENT; ANTIGEN DETECTION; ARTICLE; CHILD; COMPUTER PROGRAM; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE SEQUENCE; DYSPEPSIA; ENDOSCOPY; FECES ANALYSIS; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HISTOLOGY; HUMAN; HUMAN TISSUE; INFANT; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STRUCTURED QUESTIONNAIRE; TREATMENT OUTCOME;

ABDOMINAL PAIN; ADOLESCENT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BIOPSY; CHILD; CHILD, PRESCHOOL; CLARITHROMYCIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; DYSPEPSIA; FECES; FEMALE; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; KENYA; MALE; METRONIDAZOLE; TREATMENT OUTCOME;

EID: 84889600712     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/samj.7012     Document Type: Article

References (19)

1. Vaira D, Gatta L, Ricci C, et al. Helicobacter pylori: Diseases, tests and treatment. Dig Liv Dis 2001; 33(9): 788-794. [http://dx. doi. org/10. 1016/S1590-8658(01)80697-6].
2. Ozen A, Ertem D, Pehlivanoglu E. Natural history and symptomatology of Helicobacter pylori in childhood and factors determining the epidemiology of infection. J Pedriatr Gasroenterol Nutr 2006; 42(4): 398-394. [http://dx. doi. org/10. 1097/01. mpg. 0000215307. 48169. 7b].
3. Talley NJ, Vakil N. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005; 100(10): 2324-2337. [http://dx. doi. org/10. 1111/j. 1572-0241. 2005. 00225. x].
4. Blaser MJ, Chyou PH, Nomura A. Age at establishment of H. pylori infection and gastric carcinoma, gastric ulcer and duodenal ulcer risk. Cancer Res 1995; 55(3): 562-565.
5. Agha A, Graham DY. Evidence-based examination of the African enigma in relation to Helicobacter pylori infection. Scand J Gastroenterol 2005; 40(5): 523-529. [http://dx. doi. org/10. 1080/00365520510012280].
6. Feldman RA. Epidemiologic Observations and Open Questions about Disease and Infection Caused by Helicobacter Pylori. In: Achtman M, Suerbaum S, eds. Helicobacter pylori: Molecular and Cellular Biology. Wymondham, UK: Horizon Scientific Press, 2001: 29-51.
7. Lam S, Talley N. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13(1): 1-12. [http://dx. doi. org/10. 1111/j. 1440-1746. 1998. tb00537. x].
8. Gerrits MM, van Vliet AH, Kuipers EJ, et al. Helicobacter pylori and antimicrobial resistance: Molecular mechanisms and clinical implications. Lancet Infect Dis 2006; 6(11): 699-709. [http://dx. doi. org/10. 1016/S1473-3099(06)70627-2].
9. Tanih NF, Dube C, Green E, et al. An African perspective on Helicobacter pylori: Prevalence of human infection, drug resistance, and alternative approaches to treatment. Ann Trop Med Parasitol 2009; 103(3): 189-204. [http://dx. doi. org/10. 1179/136485909X398311].
10. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of H. pylori infection: The Maastricht III Consensus Report. Gut 2007; 56(6): 772-781. [http://dx. doi. org/10. 1136/gut. 2006. 101634].
11. Laheij RJ, Rossum LG, Jansen JB, et al. Evaluation of treatment regimens to cure Helicobacter pylori infection-A meta-analysis. Aliment Pharmacol Ther 1999(7); 13: 857-864. [http://dx. doi. org/10. 1046/j. 1365-2036. 1999. 00542. x].
12. Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003; 17(5): 719-726. [http://dx. doi. org/10. 1046/j. 1365-2036. 2003. 01461. x].
13. Francavilla R, Lionetti E, Castellaneta SP, et al. Improved efficacy of 10 day sequential treatment for Helicobacter pylori eradication in children: A randomized trial. Gastroenterology 2005; 129(5): 1414-1419. [http://dx. doi. org/10. 1053/j. gastro. 2005. 09. 007].
14. Calvet X, Garcia N, Lopez T, et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14(5): 603-609. [http://dx. doi. org/10. 1046/j. 1365-2036. 2000. 00744. x].
15. Erdur, B, Ozturk, Y, Gurbuz ED, et al. Comparison of sequential and standard therapy for H. pylori eradication in children and investigation of clarithromycin resistance. J Pediatr Gastroenterol Nutr 2012; 55(5): 530-533. [http://dx. doi. org/10. 1097/MPG. 0b013e3182575f9c].
16. Kimang'a AN. A situational analysis of antimicrobial drug resistance in Africa: Are we losing the battle? Ethiop J Health Sci 2012; 22(2): 135-143.
17. Roberts MC. Resistance to macrolide, lincosamide, streptogramin, ketolide, and oxazolidinone antibiotics. Mol Biotechnol 2004; 28(1): 47-62. [http://dx. doi. org/10. 1385/MB: 28: 1: 47].
18. Sengayi M, Dwane N, Marinda E, Sipambo N, Fairlie L, Moultrie H. Predictors of loss to follow-up among children in the first and second years of antiretroviral treatment in Johannesburg, South Africa. Glob Health Action 2013; 6: 19248. [http://dx. doi. org/10. 3402/gha. v6i0. 19248].
19. Alvarez-Uria G, Naik PK, Pakam R, Midde M. Factors associated with attrition, mortality, and loss to follow up after antiretroviral therapy initiation: Data from an HIV cohort study in India. Glob Health Action 2013; 6: 21682. [http://dx. doi. org/10. 3402/gha. v6i0. 21682].